In patients with MASLD/MASH, do you perform any cardiac testing to create a patient's risk profile, given that cardiac complications are the top cause of morbidity and mortality in this patient population (especially those with advanced fibrosis)?

This is a very important question, particularly because the new ACC guidelines suggest the use of more advanced lipid markers, like Apolipoprotein B and Lipoprotein (a), in individuals who are deemed "high risk" for cardiac disease. Unfortunately, they didn't specifically mention MASLD/MASH as a ris...

Yes. I routinely perform cardiovascular risk assessment in patients with MASLD or MASH, but I recommend risk‑based cardiovascular evaluation rather than routine cardiac testing for all patients.

Cardiovascular disease is the leading cause of morbidity and mortality in MASLD and MASH, particularly in...